Virtual Event January 24-28, 2022
The scientific content of the event is brought to the audience by the Association: International Forum for Biomedical Research (IFBR).
The association fulfills the following purpose in a non-profit manner and with no economic objectives:
![]() |
Dr Klemens HOEGENAUER During a few industry internships as part of my undergraduate studies, I discovered that I could use my skills as a chemist to help generate novel treatment options for patients. Consequently, I focused on synthetic organic chemistry for both my PhD with Prof. Johann Mulzer in Vienna, Austria and my postdoctoral work with Prof. Steven V. Ley in Cambridge, UK. Following my original passion, I then started to work with Novartis as a Medicinal Chemist, a role that still continues to challenge me some 19 years later. |
||
![]() |
Dr Karl Heinz KRAWINKLER My name is Karl Heinz Krawinkler. I have been working with Novartis for the past 18 years. I am currently a Group Leader in Medicinal Chemistry and Senior Principle Scientist. I completed my PhD in Chemistry at the University of Vienna, and I am currently finishing a Master degree in Medicines Development at the University of Basel. As a firm believer in lifelong learning, I completed two Diplomas in Advanced Studies (Medicines Development and Clinical Trial Management) concurrently with my successful career in research. |
||
![]() |
Dr Antonia F. STEPAN Antonia F. Stepan is a Section Head - Medicinal Chemistry at Roche. Antonia received her undergraduate degree from the ETH Zurich, Switzerland, and her Ph.D. from the University of Cambridge, UK, under the guidance of Professor Steven V. Ley. After two years of postdoctoral studies with Professor K. C. Nicolaou at the Scripps Institute in La Jolla, California, Antonia joined the Pfizer Medicinal Chemistry Department at the end of 2008. Her research interest focused on the discovery of novel medicines for the treatment of neurodegenerative diseases. She has co-authored more than 35 peer-reviewed papers, reviews, and patents and was recognized as a ‘Young Investigator in Medicinal Chemistry' by the American Chemical Society in 2015. |